|
Q1 FY2026
As of Mar 31, 2026
|
Q4 FY2025
As of Dec 31, 2025
|
Q3 FY2025
As of Sep 30, 2025
|
Q2 FY2025
As of Jun 30, 2025
|
Q1 FY2025
As of Mar 31, 2025
|
Q4 FY2024
As of Dec 31, 2024
|
Q3 FY2024
As of Sep 30, 2024
|
Q2 FY2024
As of Jun 30, 2024
|
Q1 FY2024
As of Mar 31, 2024
|
Q4 FY2023
As of Dec 31, 2023
|
Q3 FY2023
As of Sep 30, 2023
|
Q2 FY2023
As of Jun 30, 2023
|
Q1 FY2023
As of Mar 31, 2023
|
Q4 FY2022
As of Dec 31, 2022
|
Q3 FY2022
As of Sep 30, 2022
|
Q2 FY2022
As of Jun 30, 2022
|
Q1 FY2022
As of Mar 31, 2022
|
Q4 FY2021
As of Dec 31, 2021
|
Q3 FY2021
As of Sep 30, 2021
|
Q2 FY2021
As of Jun 30, 2021
|
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Assets | ||||||||||||||||||||
| Current assets: | ||||||||||||||||||||
| Cash and cash equivalents | ||||||||||||||||||||
| Short-term investments | ||||||||||||||||||||
| Accounts receivable, net | ||||||||||||||||||||
| Inventories, net | ||||||||||||||||||||
| Prepaid clinical development costs | ||||||||||||||||||||
| Prepaid inventory costs | ||||||||||||||||||||
| Other prepaid and current assets | ||||||||||||||||||||
| Total current assets | ||||||||||||||||||||
| Property and equipment, net | ||||||||||||||||||||
| Right of use operating lease assets | ||||||||||||||||||||
| Intangible assets | ||||||||||||||||||||
| Total assets | ||||||||||||||||||||
| Liabilities and stockholders’ deficit | ||||||||||||||||||||
| Current liabilities: | ||||||||||||||||||||
| Accounts payable | ||||||||||||||||||||
| Convertible notes, net of issuance costs | ||||||||||||||||||||
| Accrued clinical development costs | ||||||||||||||||||||
| Accrued variable consideration | ||||||||||||||||||||
| Other accrued liabilities | ||||||||||||||||||||
| Royalty sale liability | ||||||||||||||||||||
| Revenue interest liability | ||||||||||||||||||||
| Deferred revenue from collaborations | ||||||||||||||||||||
| Operating lease liabilities | ||||||||||||||||||||
| Total current liabilities | ||||||||||||||||||||
| Convertible notes, net of issuance costs | ||||||||||||||||||||
| Royalty sale liability | ||||||||||||||||||||
| Revenue interest liability | ||||||||||||||||||||
| Long-term debt | ||||||||||||||||||||
| Operating lease liabilities | ||||||||||||||||||||
| Other long-term liabilities | ||||||||||||||||||||
| Total liabilities | ||||||||||||||||||||
| Stockholders’ deficit: | ||||||||||||||||||||
| Preferred stock, $0.001 par value; 5,000,000 shares authorized and no shares issued or outstanding as of March 31, 2026 and December 31, 2025 | ||||||||||||||||||||
| Common stock, $0.001 par value; 480,000,000 shares authorized as of March 31, 2026 and December 31, 2025; 259,399,074 shares issued at March 31, 2026 and 247,210,341 shares issued at December 31, 2025 | ||||||||||||||||||||
| Additional paid-in capital | ||||||||||||||||||||
| Treasury stock, at cost; 1,994,198 shares at June 30, 2023 and December 31, 2022 | ||||||||||||||||||||
| Treasury stock, at cost; 1,994,198 shares at March 31, 2026 and December 31, 2025 | ||||||||||||||||||||
| Accumulated other comprehensive loss | ||||||||||||||||||||
| Accumulated deficit | ||||||||||||||||||||
| Total stockholders’ deficit | ||||||||||||||||||||
| Total liabilities and stockholders’ deficit | ||||||||||||||||||||
| Common stock, authorized (in shares) | ||||||||||||||||||||
Loading...
